Vitamin E succinate (VES) is another mitochondrion-targeting modified drug, which inhibits both complex I and complex II, promotes the production of ROS, induces apoptosis by restoring Fas (CD95), transforms growth factor beta-mediated signaling pathways, further activates the c-Jun N-terminal kinase pathway, and is significantly being used for the management of breast cancer [47]. Here, FAS is linked to breast cancer.